Norethisterone Other names: Norethindrone 19-nor-17α-ethynyltestosterone

Chemical formula: C₂₀H₂₆O₂  Molecular mass: 298.419 g/mol  PubChem compound: 6230

Therapeutic indications

Norethisterone is indicated for:

Dysfunctional uterine bleeding, polymenorrhoea, menorrhagia, dysmenorrhoea, metropathia haemorrhagia

Population group: women, only adults (18 - 65 years old)

at least one of
Anovular menstruation
Polymenorrhea
Menorrhagia
Period pain
Metropathia hemorrhagica

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Endometriosis

Population group: women, only adults (18 - 65 years old)

Endometriosis (clinical)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Postponement of menstruation

Population group: women, only adults (18 - 65 years old)

Drug treatment to delay menstruation

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pre-menstrual syndrome

Population group: women, only adults (18 - 65 years old)

Premenstrual tension syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Disseminated breast carcinoma

Population group: only adults (18 years old or older)

CA - Carcinoma of breast

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Norethisterone is contraindicated in the following cases:

Porphyria

Porphyria

Pregnancy

Pregnancy

Undiagnosed irregular vaginal bleeding

Observations of vaginal bleeding

Severe pruritus, pemphigoid gestationis

at least one of
Itching of skin
Herpes gestationis

Disturbance of liver function

Hepatopathy

Arterial thromboembolic disease

at least one of
Arterial embolic and thrombotic occlusion
Arterial thrombosis

Venous thromboembolism

Thromboembolism of vein

Hypersensitivity to norethisterone

Norethisterone allergy

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL) 2020: JENCYCLA Tablet
Summary of Product Characteristics (SPC) 2019: UTOVLAN Tablet
Summary of Product Characteristics (SPC) 2018: PRIMOLUT N Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈